Skip to content

Scailyte Quarterly Update December 2021

Scailyte’s quarterly report December 2021 on the progress towards its mission to save millions of lives

Scailyte quarterly update

Scailyte quarterly update, highlighting the successful first closing of the Series A financing round and the three new patents filed on the discoveries. Scailyte has appointed a new Chief Operating Officer with executive pharma background, Corinne Solier. Here is a quote from Corinne – “The next revolution will be realized when we can fully harness the power of single-cell biological information to discover new and more sensitive biomarkers of diagnostic, predictive and prognostic value for individual patients. Scailyte’s perfectly suited capabilities, as well as the passionate and excellent team, convinced me to join the company, to fulfil our mission of advancing precision medicine.” Read more below:

Read our previous quarterly update here

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

PAPER: Mapping single-cell data - Nature Biotech

Large single-cell atlases are now routinely generated to serve as references for the analysis of sma

Read more

Recent News

Scailyte Closes Financing Round and Onboards Top Biotech Leaders

Scailyte has successfully finished the first closing of their series A. Two new investors joined the

Read more

Recent News

Scailyte Quarterly Update December 2021

December 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

Why single-cell technologies are vital for Endometriosis research webinar

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

01 /04

PAPER: Mapping single-cell data - Nature Biotech

Large single-cell atlases are now routinely generated to serve as references for the analysis of sma

Read more

Scailyte Closes Financing Round and Onboards Top Biotech Leaders

Scailyte has successfully finished the first closing of their series A. Two new investors joined the

Read more

Recent News

02 /04

Scailyte Quarterly Update December 2021

December 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

03 /04

Why single-cell technologies are vital for Endometriosis research webinar

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

04 /04

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News